Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Changes to CDC website spark debate over autism and vaccine misinformation - 2Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
- 325 Years Ago, Audi's Rosemeyer Concept Was A Steampunk Supercar With A Massive Engine
- 4Astronaut on ISS captures spectacular orbital video of zodiacal light, auroras and the Pleiades
- 5Iran Used $2 Billion in Crypto to Run Its Militant Proxies in 2025
- Becoming the best at Discussion: Individual Procedures
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- Dominating the Art of Composing: Creator Bits of knowledge
- Charlotte faith leaders hold interfaith forum on Black and Palestinian solidarity
- The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- 2026 will be the year NASA astronauts fly around the moon again — if all goes to plan
- Israel approves 19 new West Bank settlements in major annexation push
- 4 Jeep Models: Dominating Execution and Flexibility for Each Experience
